Navigation Links
ViroPharma to Participate In Three May Healthcare Investor Conferences

EXTON, Pa., April 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 36th Annual Healthcare Conference at 10:40 A.M. ET on Tuesday, May 3, 2011.  The conference is being held at the InterContinental Hotel in Boston, MA.

Vincent Milano, president and chief executive officer of ViroPharma, will present at the Bank of America/Merrill Lynch 2011 Healthcare Conference at 3:40 P.M. PT (6:40 P.M. ET) on Wednesday, May 11, 2011.  The conference is being held at the Wynn Hotel in Las Vegas, NV.

William Roberts, vice president, corporate communications of ViroPharma will present at the ThinkEquity 2nd Annual Healthcare Conference at 11:30 A.M. ET on Wednesday, May 25, 2011. The conference is being held at the Princeton Club in New York City.

ViroPharma's presentations will be webcast live for investors through and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015   Rosa & Co. ... in Quantitative Systems Pharmacology (QSP)/ PhysioPD™ , today announced ... lead a workshop at the QSP Congress Meeting ... Boston, MA.  The conference focuses on ... development.  Dr. Friedrich,s workshop is entitled "Using Mechanistic Physiological ...
(Date:10/13/2015)... World Thrombosis Day Interactive Infographic ...   --> World Thrombosis Day Interactive ... promote vital global awareness of thrombosis, its causes, ... the formation of potentially deadly blood clots in ... thromboembolism (VTE) - or the artery (arterial thrombosis) [1] ...
(Date:10/12/2015)... Apheresis is an invasive process that involves ... other components from whole blood. In this procedure, the blood ... apheresis machine or a blood cell separator. The apheresis equipment ... blood components. A selected part of the blood is removed, ... the patient. It involves the use of devices and disposables ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced today their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user ... Green Valley Ranch and will unite customers, partners, WennSoft team members and sponsors ...
(Date:10/13/2015)... ... ... Scientists in Seattle and Vancouver compared the diagnostic value of lung fluid ... Mesothelioma has just posted an article on the new research. Click here to ... University of British Columbia found that certain genetic alterations were seen just as often ...
(Date:10/13/2015)... GA (PRWEB) , ... October 13, 2015 , ... ... nonprofit promoting the establishment of telemedicine programs in communities throughout Georgia, along with ... announce the collective schedule for their regional telehealth summits for Fall 2015. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... new School of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from ... education that has spanned four decades. , Dr. McLeod’s long and successful nursing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, ... Conference on August 26. Berry, who owns and operates Gold's Gym Cheyenne ... growing Gold’s Gyms in the United States. A brand leader in global fitness, Gold’s ...
Breaking Medicine News(10 mins):